
    
      It is an open, single-arm, single-center clinical trial conducted in China, and plan to
      Recruiting 38 patients (â‰¥65 years old, ECOG PS 0-2) who were progressed after first line
      systemic therapy and refused/can't tolerate chemotherapy. Patents receive 12mg anlotinib
      orally daily on day 1to 14 of a 21-day cycle until progression of disease, assess safety and
      efficacy of the drug.
    
  